TokenPost·
Bolt Biotherapeutics Posts Q3 GAAP Loss of $2.25 Per Share
The Nasdaq-listed company trades under the symbol BOLT.
More news
- TokenPostThe LGL Group Revenue Rises 32.1% in Q3 2026 as It Posts a $45,000 Net Loss
- TokenPostBitcoin Leads Five Perpetual-Futures Markets With $7.23 Billion in Open Interest
- TokenPostFRMO Posts $800,000 in Q1 Revenue, $0.19 Non-GAAP Loss Per Share
- TokenPostNew Concept Energy Posts $37,000 in Q3 Revenue and $11,000 Net Loss
- TokenPostBadger Prices C$200 Million in Senior Unsecured Notes Due in 2033
- TokenPostAnthropic Opens Claude Meetings Beta for Team and Enterprise Users